2015 ACR/ARHP Annual Meeting

November 6-11, 2015. San Francisco, CA.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 345

Relationship Between Total Hip BMD T-Score and Incidence of Nonvertebral Fracture with up to 8 Years of Denosumab Treatment
Abstract Number: 238

Relationship Between Ultrasonographic Synovial Inflammation and Ultrasonographic Urate Deposition Findings in Patients with Gout
Abstract Number: 1893

Relationship Between Vitamin D Levels and Disease Activity in Patients with Systemic Sclerosis
Abstract Number: 418

Relationship of Race, Ethnicity, and Outcomes in Pediatric Localized Scleroderma: Possible Differences in Disease Activity
Abstract Number: 2307

Relationship of Sleep Quality and Fibromyalgia Outcomes in a Phase 2b Randomized, Double-Blind, Placebo-Controlled Study of Bedtime, Rapidly Absorbed, Sublingual Cyclobenzaprine (TNX-102 SL)
Abstract Number: 2868

Relative Efficacy of Adalimumab Versus Secukinumab in Active Psoriatic Arthritis: A Matching-Adjusted Indirect Comparison
Abstract Number: 2961

Reliability and Validity of the Total Joint Count and Swollen Joint Count in Early Diffuse Systemic Sclerosis
Abstract Number: 1726

Reliability of Radiographic Assessment of Psoriatic Arthritis Mutilans
Abstract Number: 295

Reliability of the Cutaneous Dermatomyositis Disease Area and Severity Index Among Dermatologists, Rheumatologists, and Neurologists
Abstract Number: 827

Reliability of the Quantitative Assessment of Peripheral Blood Perfusion By Laser Speckle Contrast Analysis in a Systemic Sclerosis Cohort
Abstract Number: 1725

Reliable Evaluation of Structural Lesions of the Sacroiliac Joints on MRI in Patients with Axial Spondyloarthritis That Is Comparable to Evaluation of Inflammation Despite Minimal Calibration
Abstract Number: 3222

Repeated Administration of Dapirolizumab Pegol (DZP) Appears Safe and Well Tolerated in Patients with Systemic Lupus Erythematosus (SLE) and Is Accompanied By an Improvement in Disease Activity: Results from a Phase 1 Study
Abstract Number: 637

Repeated B Lymphocyte Depletion Therapy with Rituximab in Sjögren’s Syndrome: A Single Center Experience
Abstract Number: 1656

Repeated CD4+ T-Cell Depletion in Patients with Rheumatoid Arthritis over Multiple Cycles of Rituximab Treatment
Abstract Number: 2024

Replacing Radiographic Sacroiliitis By Structural Lesions on MRI of the Sacroiliac Joints in Two Early Axial Spa Cohorts: What Is the Impact on the Classification of Patients According to the ASAS Axial Spa Criteria?

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].